List of Excipients in Branded Drug PENICILLIN V POTASSIUM

Generic Drugs Containing PENICILLIN V POTASSIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	penicillin v potassium	0093-1172	ANHYDROUS TRISODIUM CITRATE
Teva Pharmaceuticals USA Inc	penicillin v potassium	0093-1172	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Teva Pharmaceuticals USA Inc	penicillin v potassium	0093-1172	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in PENICILLIN V POTASSIUM?

# Of NDCs	Excipient
5	ANHYDROUS TRISODIUM CITRATE
5	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
104	CELLULOSE, MICROCRYSTALLINE

Penicillin V Potassium Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Penicillin V potassium is an established, off-patent oral antibiotic with limited molecule-level exclusivity and a largely generic commercial base. The strongest opportunities are in differentiated dosage forms, pediatric acceptability, reconstitution stability, preservative and excipient tolerability, supply reliability, and institutional packaging rather than in conventional patent protection.

The active ingredient is phenoxymethylpenicillin potassium, an orally administered penicillin used for susceptible bacterial infections, including streptococcal pharyngitis and selected respiratory, skin, and dental infections. FDA-approved products include tablets and powders for oral solution or suspension. Product economics are constrained by low pricing, antimicrobial stewardship, short treatment courses, and competition from other oral antibiotics. [1][2]

What excipients are used in penicillin V potassium products?

Penicillin V potassium products use different excipient systems depending on the dosage form, manufacturer, strength, and market.

Tablet excipients

Immediate-release tablets commonly require excipients for:

• Dilution of the relatively low-dose active ingredient
• Powder flow and content uniformity
• Granulation and compression
• Tablet disintegration
• Film coating, where applicable
• Moisture protection
• Identification through color or imprinting

Typical excipient classes include lactose or other fillers, microcrystalline cellulose, starches, povidone, crospovidone, magnesium stearate, colloidal silicon dioxide, and coating polymers. The exact composition is product-specific and must be confirmed against the approved labeling and FDA Inactive Ingredient Database. [3][4]

The principal formulation risks are moisture uptake, blend segregation, inadequate disintegration, and patient reactions to excipients such as lactose, colorants, or certain film-coating components.

Powder for oral solution or suspension

Liquid products generally contain:

• A bulking agent such as sucrose
• Suspending or viscosity-modifying agents
• Wetting agents
• Flavoring agents
• Sweeteners
• Buffers or pH modifiers
• Preservatives, where used
• Colorants, where used
• Anti-caking or flow-control agents in the dry powder

Many penicillin V potassium pediatric products are supplied as dry powders that are reconstituted with water before dispensing. The dry state improves product stability and simplifies transportation. Once reconstituted, the product has a shorter usable period and requires controlled storage according to the approved label. [1][2]

A critical distinction is that an oral solution is molecularly dissolved, while an oral suspension contains dispersed drug particles. Suspension products need controlled particle size, wetting, sedimentation behavior, redispersibility, and dose uniformity throughout the in-use period.

What excipient strategy best supports commercial differentiation?

The most attractive strategy is to develop a reliable pediatric liquid platform with improved palatability, simple dosing, and a controlled excipient profile.

Pediatric taste-masking strategy

Penicillin V potassium has an unpleasant taste that can reduce adherence, particularly in children. Commercially relevant approaches include:

• Fruit flavor systems that remain stable across the product’s pH range
• High-intensity sweeteners used with reduced sucrose
• Polymer-based taste masking
• Ion-exchange resins or encapsulated drug particles
• Viscosity control that reduces immediate contact with taste receptors
• Lower-volume, higher-concentration dosing where clinically appropriate

A taste-masking program must preserve dissolution, dose uniformity, antimicrobial potency, and reconstitution performance. Excessive viscosity can make oral syringes difficult to use and can increase dosing variability.

A strong product concept is a low-volume, flavored suspension with a dosing syringe and a clear reconstitution mark on the bottle. That combination addresses caregiver burden without relying solely on flavor intensity.

Sugar-free and low-sugar formulations

Conventional pediatric antibiotic liquids often use sucrose for palatability and bulk. Sugar-free or reduced-sugar products can target:

• Children with diabetes or dietary restrictions
• Dental-sensitive populations
• Hospitals seeking lower sugar exposure
• Caregivers who prefer reduced-sugar medicines
• Markets with strong excipient-labeling requirements

Polyols such as sorbitol or xylitol can introduce gastrointestinal tolerability issues. High-intensity sweeteners can create aftertaste and may require a blended flavor system. A sugar-free formulation therefore has a genuine development tradeoff rather than a simple substitution opportunity.

Preservative strategy

Preservatives may support microbiological control in multidose liquids, but they can also create regulatory and market barriers. A preservative-free product may command a niche position if it uses:

• Single-dose packaging
• Unit-dose oral syringes
• A dry powder dispensed close to the time of use
• A validated in-use period supported by packaging and handling controls
• A delivery device that minimizes repeated bottle opening

A preservative-free multidose product requires strong microbiological data and a packaging system that limits contamination. Preservative selection must account for compatibility with the active ingredient, flavor components, container closure, and target population.

What formulation patents could protect penicillin V potassium products?

Formulation patents could protect a specific excipient combination, delivery system, particle-engineering process, taste-masking method, or stability profile. They would not restore broad exclusivity over penicillin V potassium itself.

Potentially protectable technical features include:

Technical area	Potential claim subject matter	Commercial value
Taste masking	Coated particles, resin complexes, or encapsulated potassium penicillin V	High for pediatric products
Liquid stability	Specific buffer, preservative, pH, and storage system	Moderate
Dry powder	Improved flow, rapid reconstitution, or reduced caking	Moderate
Low-volume suspension	Higher concentration with acceptable viscosity and dose uniformity	High
Device packaging	Unit-dose syringe, bottle adapter, or controlled reconstitution package	Moderate
Excipient-free formulation	Reduced-allergen or dye-free composition	Niche
Manufacturing process	Particle-size control, granulation, or coating process	Moderate if difficult to design around

Patentability would depend on novelty, non-obviousness, enablement, and claim scope. A patent directed only to routine use of conventional sweeteners, flavors, or suspending agents would face a weak patentability position. A stronger application would link the excipient system to measured improvements in potency retention, taste response, reconstitution time, sedimentation, syringeability, or in-use stability.

When does penicillin V potassium lose exclusivity?

Penicillin V potassium lost meaningful molecule-level exclusivity decades ago. It is a legacy generic medicine rather than a product approaching first generic entry.

The active ingredient was introduced in the mid-20th century, and current U.S. products are marketed through abbreviated new drug applications or legacy approvals rather than through a modern branded exclusivity model. FDA pediatric, orphan, or new chemical entity exclusivities do not generally create a current commercial barrier for standard penicillin V potassium tablets or oral liquids. [1][5]

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	None for this legacy active ingredient
Standard five-year generic delay	Not applicable to the established molecule
Three-year new clinical investigation exclusivity	Not generally relevant to standard products
Orphan-drug exclusivity	Not applicable to routine indications
Pediatric exclusivity	No general current barrier identified
Formulation patent exclusivity	Possible only for a novel, claim-supported product
Method-of-use patent	Limited relevance for established indications

A company pursuing a new formulation would need to create its own protectable IP position. The existence of an approved penicillin V potassium tablet would not prevent development of a differentiated liquid, but any patent claims would need to avoid routine formulation language.

What is the Orange Book status of penicillin V potassium?

The FDA Orange Book identifies approved drug products and patent or exclusivity information where applicable. For penicillin V potassium, the commercial landscape is dominated by generic approvals and legacy products. The relevant Orange Book review should focus on current listed dosage forms, strengths, therapeutic equivalence codes, and any active patent or exclusivity entries associated with the specific reference product. [5]

A generic applicant should assess:

1. Whether the targeted strength has a current reference-listed drug.
2. Whether the dosage form is tablet, powder for oral solution, or suspension.
3. Whether the product requires a bioequivalence approach suited to the dosage form.
4. Whether any listed patents apply to the targeted product.
5. Whether the proposed formulation contains excipients that create labeling or safety concerns.
6. Whether the product is eligible for an abbreviated new drug application rather than a new drug application.

Because the active ingredient is old, the principal regulatory burden is product quality, bioequivalence, microbiological control, and manufacturing consistency. The commercial risk is usually market size and price erosion rather than patent litigation.

Which companies are challenging penicillin V potassium patents?

No major current Paragraph IV campaign is associated with the core penicillin V potassium molecule. The product is already widely genericized, and the low commercial value of standard tablets reduces the incentive for high-cost patent litigation.

Paragraph IV risk could arise if a company launches a new formulation protected by a later patent. Potential challengers could target:

• A pediatric taste-masked suspension
• A high-concentration formulation
• A preservative-free multidose product
• A specialized packaging system
• A new method of use supported by clinical data

Such disputes would concern the formulation or method claims, not the underlying antibiotic molecule. A later entrant could also design around narrow excipient claims by changing the flavor system, polymer, particle size, concentration, or packaging configuration.

What FDA regulatory pathway applies to new penicillin V potassium formulations?

A conventional generic tablet or oral suspension would generally use the ANDA pathway if a suitable reference-listed drug and bioequivalence framework are available. [5][6]

A reformulated product may require a different pathway when it introduces a material clinical or delivery distinction. Examples include:

• A new concentration that changes dosing volume
• A novel delivery device
• A product with clinically meaningful pharmacokinetic differences
• A new indication
• A formulation that cannot rely on conventional bioequivalence methods

FDA review will focus on identity, strength, quality, purity, stability, dissolution, content uniformity, microbiological quality, and bioequivalence. For oral suspensions, FDA also evaluates particle size, redispersibility, dose delivery, and the ability of the product to remain uniform during use. [6]

What manufacturing and intellectual-property barriers exist?

The active ingredient is commercially accessible, but manufacturing quality still presents barriers.

Manufacturing barriers

Key risks include:

• Potency loss during wet granulation or prolonged exposure to moisture
• Inconsistent potassium penicillin V assay
• Segregation in low-dose tablet blends
• Poor powder flow
• Caking during storage
• Slow or incomplete reconstitution
• Sedimentation and hard cake formation
• Microbial contamination after reconstitution
• Flavor instability
• Interaction between preservatives and suspension polymers
• Packaging moisture ingress

A dry powder product requires control of bulk density, particle-size distribution, moisture, reconstitution time, and bottle headspace. Tablet products require robust compression and packaging controls.

Intellectual-property barriers

A defensible patent estate would typically need several layers:

1. Composition claims covering the specific excipient system.
2. Particle or coating claims covering taste-masked drug particles.
3. Process claims covering manufacture of the formulation.
4. Packaging claims covering reconstitution or multidose delivery.
5. Method claims tied to a specific patient population or administration advantage.

A single broad formulation patent is unlikely to provide durable protection. The strongest strategy is a narrow but technically demonstrated portfolio supported by comparative data.

How does penicillin V potassium compare with competing oral antibiotics?

Penicillin V potassium competes with low-cost oral antibiotics, including amoxicillin and other beta-lactams. Amoxicillin generally has stronger pediatric commercial positioning because of broad liquid availability, familiar dosing, and extensive use in respiratory and dental indications. Penicillin V potassium retains a role where narrow-spectrum therapy is clinically preferred, particularly for susceptible streptococcal infections. [2][7]

Commercial factor	Penicillin V potassium	Amoxicillin
Spectrum	Narrower	Broader
Pediatric liquid demand	Established but smaller	Generally stronger
Taste and adherence challenge	Significant	Product-dependent
Generic competition	Mature	Mature
Molecule-level patent opportunity	None	None for conventional products
Formulation opportunity	Taste, concentration, packaging	Taste, concentration, combination products
Stewardship positioning	Favorable where appropriate	Broader exposure may limit use in some cases

A penicillin V potassium product can compete through adherence, availability, and stewardship positioning rather than through broad-spectrum coverage.

What commercial opportunities exist for penicillin V potassium?

The most credible opportunities are niche generic products with operational or patient-use advantages.

Highest-value opportunities

Product concept	Target customer	Opportunity assessment
Improved-taste pediatric suspension	Pediatric prescribers and caregivers	Strongest formulation opportunity
Sugar-free suspension	Hospitals and caregivers	Moderate, with excipient tradeoffs
Dye-free, allergen-conscious product	Retail and institutional markets	Niche
High-concentration liquid	Caregivers and pharmacies	Moderate if stability and syringeability are demonstrated
Unit-dose packaging	Hospitals, clinics, emergency departments	Moderate
Reliable shortage-resistant supply	Wholesalers and health systems	Strong operational value
Ready-to-use liquid	Pharmacies and caregivers	Potentially attractive, but stability burden is high
Contract-manufactured private-label product	Regional distributors	Moderate

Revenue exposure

Standard penicillin V potassium is unlikely to support premium branded pricing. Revenue depends on unit volume, distribution reach, supply continuity, and manufacturing cost. The most defensible commercial model is a low-cost product with a differentiated presentation that reduces substitution and improves pharmacy preference.

Hospital and public-sector contracts may be more valuable than retail premium pricing. A supplier with dependable API sourcing, validated secondary manufacturing, and consistent liquid availability can gain share during competitor shortages even without strong patent protection.

What is the likely generic launch risk?

For standard tablets, generic launch risk is high because the market is mature and formulation differentiation is limited. For a novel pediatric liquid, risk is more nuanced.

Product type	Generic entry risk	Main reason
Standard tablet	High	Mature product with limited differentiation
Conventional powder for oral solution	High	Established technology and low formulation complexity
Sugar-free liquid	Moderate	Excipients and palatability create development work
Taste-masked coated suspension	Moderate to lower	Process and patent barriers may be stronger
Novel high-concentration product	Moderate	Stability and bioequivalence may complicate entry
Proprietary package and device	Moderate	Design-around remains possible

A successful product should avoid relying on a single patent. Regulatory know-how, validated taste performance, reliable supply, customer contracts, and manufacturing cost can provide practical barriers after patent expiry.

Key Takeaways

• Penicillin V potassium is an old, fully genericized oral antibiotic with no meaningful molecule-level exclusivity.
• The primary commercial opportunity is differentiated formulation, especially pediatric taste masking and low-volume liquid delivery.
• Excipients should be selected around stability, palatability, redispersibility, microbiological control, and dosing accuracy.
• Sugar-free, dye-free, preservative-free, and unit-dose products can target defined niches but require careful tolerability and stability evaluation.
• Standard tablets face high generic competition and limited pricing power.
• A later formulation patent could protect a specific composition, process, particle system, or delivery package, but not the core active ingredient.
• The strongest commercial moat is likely to combine formulation IP, supply reliability, device usability, and institutional distribution.
• FDA regulatory risk centers on product quality, bioequivalence, in-use stability, and suspension performance rather than on active-ingredient exclusivity.

FAQs

Can penicillin V potassium be formulated as a sugar-free suspension?

Yes. Sugar-free formulations can use polyols, high-intensity sweeteners, or a combination of both. The formulation must address aftertaste, gastrointestinal tolerability, viscosity, microbial control, and dose uniformity.

Is penicillin V potassium suitable for a ready-to-use liquid product?

Potentially, but a ready-to-use liquid creates greater stability and microbiological-control demands than a dry powder. The commercial benefit is simpler dispensing and improved caregiver convenience.

Can taste masking of penicillin V potassium support a new patent?

Yes, if the product has a novel and non-obvious taste-masking system supported by comparative data. Routine flavor or sweetener substitution is less likely to provide strong patent protection.

Does penicillin V potassium require a biosimilar strategy?

No. Penicillin V potassium is a small-molecule antibiotic, not a biologic. Biosimilar regulation does not apply. Generic drug approval and bioequivalence rules are the relevant framework.

Which packaging format offers the best commercial differentiation?

A dry powder in a moisture-resistant bottle with an oral-syringe-compatible adapter is a practical baseline. Unit-dose or ready-to-use packaging can offer greater differentiation but generally increases manufacturing and stability costs.

References

1. DailyMed. (n.d.). Penicillin V potassium drug labels. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Penicillin V potassium prescribing information. FDA.
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
6. U.S. Food and Drug Administration. (2022). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.
7. Centers for Disease Control and Prevention. (n.d.). Clinical guidance for group A streptococcal pharyngitis. CDC.